Literature DB >> 25564417

Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study.

Giovanni Abbruzzese1, Paolo Barone, Roberto Ceravolo, Giovanni Fabbrini, Patrizia Lessi, Alessandra Ori, Lucia Simoni, Michele Tinazzi, Angelo Antonini.   

Abstract

To assess over a period of 9 months in a sample of Italian Parkinson's disease (PD) patients reasons leading the neurologist to modify dopaminergic treatment and patients' causes of dissatisfaction with ongoing therapy. To evaluate the influence of disease severity on therapy persistence. A disease severity balanced sample of PD patients with stable anti-parkinsonian drugs (APD) treatment was enrolled and evaluated every 3 months. Patients requiring APD treatment modifications were discontinued from the study. The probability to modify APD treatment is greater for higher motor (UPDRS scores) and non-motor symptoms (NMSS score) severity. Both from neurologist's and patient's perspective, motor symptoms were the main determinants underlying APD treatment modifications. Non-motor symptoms were cause of dissatisfaction with ongoing APD treatment for 52 % of the patients, while only 36 % of the neurologists considered these as valid reasons for therapy change. REASON is the first study in PD patients that prospectively examined reasons driving APD treatment changes. Results show that the disease severity significantly increases the probability of APD treatment change. Patients attribute greater relevance than neurologists to non-motor symptoms as reason requiring treatment changes. This confirms that patient and neurologist perceptions only partially overlap.

Entities:  

Mesh:

Year:  2015        PMID: 25564417     DOI: 10.1007/s10072-014-2060-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

1.  Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.

Authors:  Marcy L Tarrants; Michel F Denarié; Jane Castelli-Haley; Jennifer Millard; Dongmu Zhang
Journal:  Am J Geriatr Pharmacother       Date:  2010-08

2.  Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study.

Authors:  Michele Tinazzi; Giovanni Abbruzzese; Angelo Antonini; Roberto Ceravolo; Giovanni Fabbrini; Patrizia Lessi; Paolo Barone
Journal:  Parkinsonism Relat Disord       Date:  2013-08-28       Impact factor: 4.891

3.  Treatment of Parkinson's disease: a survey of patients and neurologists.

Authors:  Matthias Fargel; Bernd Grobe; Eberhard Oesterle; Claudia Hastedt; Markus Rupp
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 4.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 5.  Treatments for Parkinson disease--past achievements and current clinical needs.

Authors:  Werner Poewe
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

Review 6.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

Review 7.  Therapy adherence issues in Parkinson's disease.

Authors:  Donald Grosset
Journal:  J Neurol Sci       Date:  2009-09-29       Impact factor: 3.181

  7 in total
  4 in total

1.  Disease progression in Parkinson subtypes: the PPMI dataset.

Authors:  Darko Aleksovski; Dragana Miljkovic; Daniele Bravi; Angelo Antonini
Journal:  Neurol Sci       Date:  2018-08-14       Impact factor: 3.307

2.  Transgenerational latent early-life associated regulation unites environment and genetics across generations.

Authors:  Debomoy K Lahiri; Bryan Maloney; Baindu L Bayon; Nipun Chopra; Fletcher A White; Nigel H Greig; John I Nurnberger
Journal:  Epigenomics       Date:  2016-03-07       Impact factor: 4.778

3.  Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study.

Authors:  Alessandro Stefani; Alessandro Tessitore; Nicola Tambasco; Giovanni Cossu; Maria Gabriella Ceravolo; Giovanni Defazio; Francesca Morgante; Silvia Ramat; Gabriella Melzi; Giuliana Gualberti; Rocco Merolla; Koray Onuk; Leonardo Lopiano
Journal:  BMC Neurol       Date:  2022-01-28       Impact factor: 2.474

4.  Treatment Satisfaction and Its Influencing Factors in Parkinson's Disease: A Web-Based Survey of Patients and Physicians in Clinical Practice in Japan.

Authors:  Masahiro Nomoto; Ayako Hayashi; Hiroyuki Ida; Masaki Arai
Journal:  Parkinsons Dis       Date:  2022-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.